Biotechnology Industry: Top companies Revenue, Financial Benchmarks, Metrics, P&L, KPIs and Analytics Historical (2015 to 2025) and Forecasts to 2031

This comprehensive industry report delivers a deep-dive financial and strategic analysis of the Biotechnology Industry, which operates within the broader Industrials sector. It offers an authoritative view of sector-wide performance, highlighting vital financial benchmarks, multi-year revenue trajectories, profitability indicators, and other key operational metrics. Spanning the historical period from 2015 to 2024 and extending with forward-looking projections through 2031, the report equips decision-makers with forward-thinking insights into evolving market dynamics, demand drivers, economic headwinds, and strategic KPIs. Detailed side-by-side comparisons of leading corporations are included, covering average ratios, financial performance metrics, and business fundamentals—allowing investors, analysts, and corporate planners to confidently assess industry trends and stakeholder positioning. Whether you're evaluating efficiency, profitability, expansion viability, or broader market competitiveness, this report delivers a full-spectrum view of the financial underpinnings of the Biotechnology Industry. It is an essential tool for strategic planning, benchmarking, investor presentations, and business development, helping users to understand both historical cycles and anticipate future industry transformation.

Biotechnology Industry: Top companies Revenue, Financial Benchmarks, Metrics, P&L, KPIs and Analytics Historical (2015 to 2025) and Forecasts to 2031

This comprehensive industry report delivers a deep-dive financial and strategic analysis of the Biotechnology Industry, which operates within the broader Healthcare sector. It offers an authoritative view of sector-wide performance, highlighting vital financial benchmarks, multi-year revenue trajectories, profitability indicators, and other key operational metrics. Spanning the historical period from 2015 to 2024 and extending with forward-looking projections through 2031, the report equips decision-makers with forward-thinking insights into evolving market dynamics, demand drivers, economic headwinds, and strategic KPIs. Detailed side-by-side comparisons of leading corporations are included, covering average ratios, financial performance metrics, and business fundamentals—allowing investors, analysts, and corporate planners to confidently assess industry trends and stakeholder positioning. Whether you're evaluating efficiency, profitability, expansion viability, or broader market competitiveness, this report delivers a full-spectrum view of the financial underpinnings of the Biotechnology Industry. It is an essential tool for strategic planning, benchmarking, investor presentations, and business development, helping users to understand both historical cycles and anticipate future industry transformation.

ADOCIA

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of ADOCIA. ADOCIA business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of ADOCIA are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of ADOCIA , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of ADOCIA including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of ADOCIA and all latest updates of the company are provided. The 2025 version of ADOCIA report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of ADMA Biologics Inc. ADMA Biologics Inc business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of ADMA Biologics Inc are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of ADMA Biologics Inc , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of ADMA Biologics Inc including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of ADMA Biologics Inc and all latest updates of the company are provided. The 2025 version of ADMA Biologics Inc report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

Aditxt Inc.

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Aditxt Inc.. Aditxt Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Aditxt Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Aditxt Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Aditxt Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Aditxt Inc. and all latest updates of the company are provided. The 2025 version of Aditxt Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

Adicet Bio Inc.

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Adicet Bio Inc.. Adicet Bio Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Adicet Bio Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Adicet Bio Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Adicet Bio Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Adicet Bio Inc. and all latest updates of the company are provided. The 2025 version of Adicet Bio Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Adial Pharmaceuticals Inc. Adial Pharmaceuticals Inc business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Adial Pharmaceuticals Inc are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Adial Pharmaceuticals Inc , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Adial Pharmaceuticals Inc including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Adial Pharmaceuticals Inc and all latest updates of the company are provided. The 2025 version of Adial Pharmaceuticals Inc report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

Addex Therapeutics Ltd American Depositary Shares

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot?Marie?Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Addex Therapeutics Ltd American Depositary Shares. Addex Therapeutics Ltd American Depositary Shares business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Addex Therapeutics Ltd American Depositary Shares are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Addex Therapeutics Ltd American Depositary Shares , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Addex Therapeutics Ltd American Depositary Shares including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Addex Therapeutics Ltd American Depositary Shares and all latest updates of the company are provided. The 2025 version of Addex Therapeutics Ltd American Depositary Shares report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

Addex Therapeutics Ltd

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot?Marie?Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Addex Therapeutics Ltd. Addex Therapeutics Ltd business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Addex Therapeutics Ltd are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Addex Therapeutics Ltd , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Addex Therapeutics Ltd including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Addex Therapeutics Ltd and all latest updates of the company are provided. The 2025 version of Addex Therapeutics Ltd report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of ADC Therapeutics SA. ADC Therapeutics SA business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of ADC Therapeutics SA are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of ADC Therapeutics SA , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of ADC Therapeutics SA including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of ADC Therapeutics SA and all latest updates of the company are provided. The 2025 version of ADC Therapeutics SA report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.